IDH1 and cholangiocarcinoma: The data reported here demonstrate that ivosidenib has a favorable PK profile in patients with IDH1-mutated solid tumors, with robust suppression of plasma 2-HG in patients with cholangiocarcinoma or chondrosarcoma.